ADCE-T02, a potential best-in-class Tissue Factor targeted antibody-drug conjugate (ADC), enters cohort expansion portion of the Tiffany-01 study in advanced solid tumorsTwo ADCE-T02 publications ...
A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...
Multitude Therapeutics out-licensed global rights (ex-Greater China) for its Tissue Factor ADC to Denmark’s Adcendo in a $1 billion agreement. Huadong Pharmaceutical acquired rights for two immune ...
SOUTH SAN FRANCISCO, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs) ...
Adcendo ApS and Multitude Therapeutics Inc. have signed a licensing agreement for the development of a highly differentiated antibody-drug conjugate (ADC) targeting tissue factor, designated ADCE-T02.
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned ...
Tissue factor (TF), a transmembrane protein overexpressed in tumors such as cervical, head and neck, NSCLC, and pancreatic cancers, initiates the extrinsic coagulation pathway under normal ...
Sutro Biopharma, Inc. announced its participation in the 2025 American Association for Cancer Research Annual Meeting, presenting key data on its novel exatecan Tissue Factor antibody drug conjugate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results